SCHEMBL13941520

SCHEMBL13941520

C/C(=N\NC(=N)N)c1ccc(NC(=O)c2cc3c(ccc4ccccc43)[nH]2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK4 O00444 1/20 0.52
▸ CHEK1 O14757 1/20 0.52
▸ AURKA O14965 1/20 0.52
▸ CHUK O15111 1/20 0.52
▸ DAPK3 O43293 1/20 0.52
▸ JAK2 O60674 1/20 0.52
▸ ROCK2 O75116 1/20 0.52
▸ PAK4 O96013 1/20 0.52
▸ CHEK2 O96017 1/20 0.52
▸ CDK1 P06493 1/20 0.52
▸ PIM1 P11309 1/20 0.52
▸ PRKACA P17612 1/20 0.52
▸ FGFR3 P22607 1/20 0.52
▸ RPS6KB1 P23443 1/20 0.52
▸ CDK2 P24941 1/20 0.52
▸ MARK3 P27448 1/20 0.52
▸ AKT1 P31749 1/20 0.52
▸ AKT2 P31751 1/20 0.52
▸ MAPK8 P45983 1/20 0.52
▸ MAPK9 P45984 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13941708 0.92 EGFR (0.52) EGFRPIK3CAALDH1A1KDM4ELMNA
SCHEMBL13941369 0.88 EGFR (0.66) PLK4CHEK1AURKACHUKDAPK3
SCHEMBL13941503 0.85 PLK4 (0.55) PLK4CHEK1AURKACHUKDAPK3
SCHEMBL13941381 0.85 EGFR (0.52) PLK4CHEK1AURKACHUKDAPK3
SCHEMBL16108828 0.83 EGFR (0.56) PLK4CHEK1AURKACHUKDAPK3
SCHEMBL13941390 0.83 EGFR (0.50) PLK4CHEK1AURKACHUKDAPK3
SCHEMBL13941451 0.83 EGFR (0.56) PLK4CHEK1AURKACHUKDAPK3
SCHEMBL13941371 0.82 RXFP1 (0.59) PLK4CHEK1AURKACHUKDAPK3
SCHEMBL13941389 0.82 EGFR (0.49) PLK4CHEK1AURKACHUKDAPK3
SCHEMBL13941375 0.82 EGFR (0.49) PLK4CHEK1AURKACHUKDAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765802-B2 Kinase inhibitors, compositions thereof, and methods of use therewith PROVID PHARMACEUTICALS, INC. (US) 2014-07-01 — — US disclosed
US-8765802-B2 Kinase inhibitors, compositions thereof, and methods of use therewith PROVID PHARMACEUTICALS, INC. (US) 2014-07-01 — — US disclosed
EP-2155675-B1 KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH PROVID PHARMACEUTICALS INC (US) 2014-02-19 — — EP disclosed
US-20090018141-A1 KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH PROVID PHARMACEUTICALS, INC. 2009-01-15 — — US disclosed
US-20090018141-A1 KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH PROVID PHARMACEUTICALS, INC. 2009-01-15 — — US disclosed
WO-2008156573-A1 KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH PROVID PHARMACEUTICALS, INC. (US) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018141-A1 KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH CHEK2, ATM, CHEK1 PLK4 231/4885CHEK1 3/4885AURKA 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback